Crescent Biopharma Inc (CBIO) has a current Price-to-Book (P/B) ratio of -5.05. Compared to its 3-year average P/B ratio of -5.32, the current P/B ratio is approximately -5.19% higher. Relative to its 5-year average P/B ratio of -5.32, the current P/B ratio is about -5.19% higher. Crescent Biopharma Inc (CBIO) has a Forward Free Cash Flow (FCF) yield of approximately -11.58%. Compared to its 3-year average FCF yield of -23.46%, the current FCF yield is approximately -50.64% lower. Relative to its 5-year average FCF yield of -23.46%, the current FCF yield is about -50.64% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CBIO competitors is 14.07, providing a benchmark for relative valuation. Crescent Biopharma Inc Corp (CBIO.O) exhibits a P/S ratio of 64.98, which is 361.89% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CBIO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CBIO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CBIO currently overvalued or undervalued?

What is Crescent Biopharma Inc (CBIO) fair value?

CBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Crescent Biopharma Inc (CBIO) is between to according to relative valuation method.

How does CBIO's valuation metrics compare to the industry average?

The average P/S ratio for CBIO's competitors is 14.07, providing a benchmark for relative valuation. Crescent Biopharma Inc Corp (CBIO) exhibits a P/S ratio of 64.98, which is 361.89% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Crescent Biopharma Inc (CBIO) as of Mar 02 2026?

As of Mar 02 2026, Crescent Biopharma Inc (CBIO) has a P/B ratio of -5.05. This indicates that the market values CBIO at -5.05 times its book value.

What is the current FCF Yield for Crescent Biopharma Inc (CBIO) as of Mar 02 2026?

As of Mar 02 2026, Crescent Biopharma Inc (CBIO) has a FCF Yield of -11.58%. This means that for every dollar of Crescent Biopharma Inc's market capitalization, the company generates -11.58 cents in free cash flow.

What is the current Forward P/E ratio for Crescent Biopharma Inc (CBIO) as of Mar 02 2026?

As of Mar 02 2026, Crescent Biopharma Inc (CBIO) has a Forward P/E ratio of -0.88. This means the market is willing to pay $-0.88 for every dollar of Crescent Biopharma Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Crescent Biopharma Inc (CBIO) as of Mar 02 2026?

As of Mar 02 2026, Crescent Biopharma Inc (CBIO) has a Forward P/S ratio of 64.98. This means the market is valuing CBIO at $64.98 for every dollar of expected revenue over the next 12 months.

CBIO Valuation